Sailong Pharmaceutical Group (002898.SZ) has been granted a supplementary drug application approval notification for Prulabalin capsules.

Sailong Pharmaceutical Group (002898.SZ) announced that its wholly-owned subsidiary, Hunan Sailong Pharmaceutical Group Co., Ltd., recently obtained the "Drug Supplementary Application Approval Notice" (Notice No.: 2024B05160) issued by the National Medical Products Administration for Pregabalin Capsules. This approval is for the treatment of post-herpetic neuralgia and fibromyalgia.